Skip to main content

Advertisement

Log in

Intravitreal injection of bevacizumab to treat neovascular glaucoma

  • Letters
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 2006;26:354–356.

    Article  PubMed  Google Scholar 

  2. Oshima Y, Sakaguchi H, Gomi F, et al. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:155–158.

    Article  CAS  PubMed  Google Scholar 

  3. Johnson M, Gong H, Freddo TF, et al. Serum protein and aqueous outflow resistance in bovine eyes. Invest Ophthalmol Vis Sci 1993;34;3549–3557.

    CAS  PubMed  Google Scholar 

  4. Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005;167:1451–1459.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695–1705.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Toshiaki Kubota.

About this article

Cite this article

Kubota, T., Aoki, R., Harada, Y. et al. Intravitreal injection of bevacizumab to treat neovascular glaucoma. Jpn J Ophthalmol 52, 410–412 (2008). https://doi.org/10.1007/s10384-008-0573-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-008-0573-3

Key Words

Navigation